British pharmaceutical company AstraZeneca has been delayed in the supply of the corona vaccines because the European Union decided late to sign a contract for the delivery, CEO Pascal Soriot told German newspaper
Die Welt on
As a result, the company did not have enough time to solve problems with external partners in the production process of the corona vaccine.
At the end of last week, it was announced that the first delivery of the AstraZeneca / Oxford vaccine to the EU will be smaller than initially expected.
According to Soriot, the volumes agreed with the EU were not binding.
"The reason we said that is because the EU wanted to be supplied more or less at the same time as the UK, even though the EU contract was signed three months later."
In August, the union bought 300 million doses of the AstraZeneca vaccine for 750 million euros.
That was after Britain ordered 100 million doses and the United States ordered 300 million doses in May.
EU President Charles Michel said earlier that the European Union will keep pharmaceutical companies by their contracts for the supply of corona vaccines.
"We plan to have pharmaceutical companies respect the contracts they have signed by using the legal means at our disposal," he said on French radio station
Governments want to know what they can count on.
This is necessary, for example, to decide whether they should keep doses on hand in order to be able to administer the necessary second injection to vaccinated people.
Otherwise they can use it for new groups.
How the AstraZeneca vaccine could be finished so quickly by a head start